Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
about
Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustinePurine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignanciesCD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab.Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia.The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.Severe Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioEffects of rhamnocitrin 4-β-D-galactopyranoside, isolated from Astragalus hamosus on toxicity models in vitro.Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agentsTreatment options for high-risk chronic lymphocytic leukaemia.Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008.Bendamustine therapy in chronic lymphocytic leukemia.Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer.Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphomaIdelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.Current and emerging new treatment strategies for mantle cell lymphoma.The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.An old drug with a new future: bendamustine in multiple myeloma.Apoptosis inducers in chronic lymphocytic leukemia.A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.Bendamustine in multiple myeloma.Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.Everolimus enhances the cytotoxicity of bendamustine in multiple myeloma cells through a network of pro-apoptotic and cell-cycle-progression regulatory proteins.Oxidative stress as a therapeutic perspective for ATM-deficient chronic lymphocytic leukemia patients.Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax.Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline.
P2860
Q27335118-A1C426D3-0C0B-4206-81F2-C312F5F0A1BBQ28540830-9BF53658-6257-4DAC-96A3-574B6AC17060Q30383411-9C541043-024C-4EDD-92CA-02CF2E0B4C7FQ33394623-4C8A3629-53AA-4299-B3F8-40810C810935Q33399400-97E81FF9-15A4-45F1-8E67-53F3E7B665E7Q33406164-3583E3CA-9ECB-4E46-8D40-A488D9B6DF99Q33411440-28C19B5C-2E77-4EDB-94F0-2248BDA01286Q33749652-6BB8A138-179B-4A5A-8914-F78210C7256CQ34181244-626F23DA-4A14-4F83-AFCB-F66CD1ECB37FQ34202277-85DF4045-B49B-4BAD-9E5F-447D5A0D6DBBQ34304491-DA761FE7-FE2E-4C8F-A79B-D070679E8067Q36293814-FD2C037E-8B39-4DF0-ADB1-B841026487BBQ36612587-8544ED20-B46C-401B-AA06-E74CDF490992Q36619787-D0B6223E-A1DC-4E55-AF80-7D94DA732184Q37269044-E2088EE2-AAF5-4430-BD67-A292C9EE355AQ37519737-659AEAE5-8AC1-4F68-9752-E4B84D68E3B5Q37705010-4DB2DE73-D180-4ECD-AF5C-5B863799F399Q37718466-55C9A9E6-9BBD-4092-A969-E95EAC66B567Q37725415-8C7BDAD7-668A-48AC-B090-6E96CB96E9F1Q38040846-60E3F277-3317-43C7-AC2F-07580FEC532AQ38056761-67427C61-1111-4BFB-9745-F44F45ED09E9Q38126946-3E1EA80D-6BB9-496D-8A00-5857C93991A4Q38139989-04B121F3-8EAF-470D-BCB4-EC38EC039FDBQ38187815-F3809B54-8F1B-4FE5-ADB2-432508CF597EQ38231432-51C7C120-23BD-458A-A82A-A5F7C5DE2C87Q38530583-6461D7D5-EBD9-45E7-9089-AC3025A08238Q38862949-B9FB30E2-5A67-4696-B05C-EA12A835F8E6Q38891225-D86B4A2A-9FAA-49EE-AE6D-86BE5E8CDEE4Q38974167-B8E410A2-ACBD-4454-8A99-0FF13000D330Q39149681-13E26482-BCF2-4AE9-A434-C1EC0462C78FQ42399864-C419CA8E-6D5E-4429-92B4-F1D301F03C54Q43584641-F9DF1288-3D7D-4742-A1AE-CC85859C72FBQ44098314-E12D5CEA-3FCE-46D5-A296-9DD3D7C0BD6FQ44633375-EB4C7DFD-3113-49F8-8684-FD65369E35B8Q52563039-EB601ED7-D2C4-49ED-BCCC-4529F32EC862
P2860
Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Bendamustine is effective in p ...... caspase-independent signaling.
@ast
Bendamustine is effective in p ...... caspase-independent signaling.
@en
Bendamustine is effective in p ...... caspase-independent signaling.
@nl
type
label
Bendamustine is effective in p ...... caspase-independent signaling.
@ast
Bendamustine is effective in p ...... caspase-independent signaling.
@en
Bendamustine is effective in p ...... caspase-independent signaling.
@nl
prefLabel
Bendamustine is effective in p ...... caspase-independent signaling.
@ast
Bendamustine is effective in p ...... caspase-independent signaling.
@en
Bendamustine is effective in p ...... caspase-independent signaling.
@nl
P2093
P50
P1476
Bendamustine is effective in p ...... caspase-independent signaling.
@en
P2093
Emili Montserrat
Mónica López-Guerra
Neus Villamor
Patricia Pérez-Galán
P304
P356
10.1158/1078-0432.CCR-08-0388
P407
P577
2008-11-01T00:00:00Z